top of page
PUBLICATIONS

  1. Holtmann GJ, Moniruzzaman M, Shah A. 2025. Decoding the gut-brain axis: A journey towards targeted interventions for disorders-of-gut-brain interaction. Digestive Diseases. doi: 10.1159/000543845. PMID: 39938496​​

  2. Moniruzzaman M*, et al. 2025. Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2, independent of common mutations. ACS Pharmacology & Translational Science, 8(2): 543-556. doi: 10.1021/acsptsci.4c00644. PMID: 39974647

  3. Sajiir H,….Moniruzzaman M, et al. 2024. Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis. Nature Communications, 15(1): 4528. doi: 10.1038/s41467-024-48317-x. PMID: 38811532.

  4. Steinmetz JD,….Moniruzzaman M, et al. 2024. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Neurology, 23 (4), 344-381. doi: 10.1016/S1474-4422(24)00038-3. PMID: 38493795.

  5. Moniruzzaman M, et al. 2024. Cannabidiol - Help and hype in targeting mucosal diseases. Journal of Controlled Release, 365: 530-543. doi: 10.1016/j.jconrel.2023.11.010. PMID: 37952828.

  6. Gurgenci T,….Moniruzzaman M, et al. 2023. Exploring potential anti-inflammatory effects of medicinal cannabis. Supportive Care in Cancer, 31(12): 629. doi: 10.1007/s00520-023-08069-8. PMID: 37837446.

  7. Moniruzzaman M, et al. 2023. Interleukin-22 suppresses MHC II in mucosal epithelial cells. Journal of Experimental Medicine, 220(11): e20230106. doi: 10.1084/jem.20230106. PMID: 37695525.

  8. Sheng YH,….Moniruzzaman M, et al. 2023. Muc13 cell surface mucin limits salmonella typhimurium infection by protecting the mucosal epithelial barrier. Cellular and Molecular gastroenterology and Hepatology, 16(6): 985-1009. doi: 10.1016/j.jcmgh.2023.08.011. PMID: 37660948.

  9. Cao Y,….Moniruzzaman M, et al. 2023. Virus-like silica nanoparticles enhance macromolecule permeation in vivo. Biomaterials Science, 11: 4508. doi: 10.1039/D3BM00137G. PMID: 37248862.

  10. Black RJ,….Moniruzzaman M, et al. 2023. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. The Lancet Rheumatology, 5(10): e594-e610. doi: 10.1016/S2665-9913(23)00211-4. PMID: 37795020.

  11. Moniruzzaman M, et al. 2023. IL-20 activates ERK1/2 and suppresses splicing of x-box protein-1 in intestinal epithelial cells but does not improve pathology in acute or chronic models of colitis. International Journal of Molecular Sciences, 24(1): 174, doi: 10.3390/ijms24010174. PMID: 36613621

  12. Janjua TI,….Moniruzzaman M, et al. 2023. Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma. Journal of Controlled Release (IF:10.50), 357: 161-174, Cites: 2

  13. Ong KL,….Moniruzzaman M, et al. 2023. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet (IF: 168.9; Q1), 402: 203–34, Cites: 4

  14. Wu D,….Moniruzzaman M, et al. 2023. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019. eClinicalMedicine, (IF: 15.10; Q1), 64: 102193.

  15. Momtazmanesh S,….Moniruzzaman M, et al. 2023. Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019. eClinicalMedicine, (IF: 15.10; Q1), 59: 101936, Cites: 2

  16. Shin YH,….Moniruzzaman M, et al. 2023. Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019. Allergy (IF: 12.40; Q1), 78(8): 2232-54

  17. Hmwe K,….Moniruzzaman M, et al. 2022. Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019. The Lancet Infectious Diseases (IF: 56.30; Q1), 22(11):1626-1647, Cites 38.

  18. Nichols E,.…Moniruzzaman M, et al. 2022. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. The Lancet Public Health (IF: 50.00; Q1), 7(2):e105-125, Cites: 900

  19. Moniruzzaman M, Elshaer D, et al. 2021. Facile synthesis of dendrimer like mesoporous silica nanoparticles to enhance targeted delivery of interleukin-22. Biomaterials Science, (IF: 6.6; Q1), 9(22):7402-7411, Cites: 4 (joint first author)

  20. Parekh K,…Moniruzzaman M, et al. 2021. Tacrolimus encapsulated mesoporous silica nanoparticles embedded hydrogel for the treatment of atopic dermatitis. International Journal of Pharmaceutics, (IF: 5.80; Q1), 608:121079, Cites: 10

  21. Wang R, Moniruzzaman M, et al. 2021. Gut microbiota shape the inflammatory response in mice with an epithelial defect. Gut Microbes (IF: 12.20; Q1), 21(1): e1887720. Cites: 15

  22. Pujara N,…..Moniruzzaman M, et al. 2021. pH-responsive colloidal carriers assembled from β-lactoglobulin and epsilon poly-l-lysine for oral drug delivery. Journal of Colloid & Interface Science (IF: 9.90; Q1), 589:45-55, Cites: 27

  23. Pujara N, Wong KY, Qu Z, Wang R, Moniruzzaman M, et al. 2021. Oral delivery of β-lactoglobulin-nanosphere-encapsulated resveratrol alleviates inflammation in Winnie mice with spontaneous ulcerative colitis. Molecular Pharmaceutics (IF:4.90; Q1), 18(2):627−640, Cites:35

  24. Qu Z, Wong KY, Moniruzzaman M, et al. 2021. One-pot synthesis of pH-responsive Eudragit-mesoporous silica nanocomposites enable colonic delivery of glucocorticoids for the treatment of inflammatory bowel disease. Advanced Therapeutics (IF: 3.70), 2000165, Cites: 25

  25. Ferdous A, …. Moniruzzaman M*. 2020. The leaves of Bougainvillea spectabilis suppressed inflammation and nociception in vivo through the modulation of glutamatergic, cGMP, and ATP-sensitive K+ channel pathways. Journal of Ethnopharmacology (The official journal of the International Society for Ethnopharmacology; IF: 4.80), 161: 113148. Cites: 15

  26. Moniruzzaman M, et al. 2019. Interleukin (IL)-22 from IL-20 subfamily of cytokines induces colonic epithelial cell proliferation predominantly through ERK1/2 pathway. International Journal of Molecular Sciences (IF: 4.90), 20(14): 3468. Cites: 27

  27. Wang R, Moniruzzaman M, et al. 2018. Immune regulation of the unfolded protein response at the mucosal barrier in viral infection. Clinical & Translational Immunology (The official journal of the Australasian Society for Immunology; IF: 4.60), 7(4): e1014. Cites: 15

  28. Moniruzzaman M*, et al. 2018. HO-1 dependent antioxidant effects of ethyl acetate fraction from Physalis alkekengi fruit ameliorates scopolamine-induced cognitive impairments. Cell Stress & Chaperones (IF: 3.30), 23(4): 763-772. Cites: 15

  29. Moniruzzaman M* et al. 2018. The leaves of Crataeva nurvala Buch-Ham. modulate locomotor and anxiety behaviors possibly through GABAergic system. BMC Complementary Medicine and Therapies (IF: 3.90), 18:283. Cites: 16

  30. Moniruzzaman M, et al. 2016. The ethyl-acetate fraction from Physalis alkekengi fruit inhibits LPS-induced pro-inflammatory mediators in BV2 cells and inflammatory pain in mice. Journal of Ethnopharmacology (IF: 4.80), 181: 26–36. Cites: 37

  31. Bose S, Kim S, Oh Y, Moniruzzaman M, et al. 2016. Effect of CCL2 on BV2 microglial cell migration: Involvement of probable signaling pathways. Cytokine (The official journal of the International Cytokine and Interferon Society; IF: 3.70), 81: 39–49. Cites: 23

  32. Ani NS, Chakraborty S, Moniruzzaman M*. 2016. The methanolic extract from Murraya koenigii L. inhibits glutamate-induced pain and involves ATP-sensitive K+ channel as antinociceptive mechanism. Advances in Pharmacological and Pharmaceutical Sciences (IF: 2.1). Article ID 3790860, 2016: 1-6. Cites: 5

  33. Moniruzzaman M* et al. 2016. Evaluation of antinociceptive activity of methanolic extract of leaves of Stephania japonica Linn. Journal of Ethnopharmacology (IF: 4.80), 186: 205-208. Cites: 14

  34. Moniruzzaman M*, et al. 2016. Sedative and anxiolytic-like actions of ethanol extract of leaves of Glinus oppositifolius (Linn.) Aug. DC. Evidence-Based Complementary and Alternative Medicine (IF: 2.65), Article ID 8541017, 2016: 1-8. Cites: 12

  35. Moniruzzaman M, et al. 2015. Antioxidant and anti-inflammatory effect of N-((3, 4-dihydro-2H-benzo[h]chromen-2-yl)methyl)-4-methoxyaniline in LPS-induced BV2 microglial cells. Biological & Pharmaceutical Bulletin (IF: 1.70), 38(12): 1831-1835. Cites: 11

  36. Moniruzzaman M, et al. 2015. Evaluation of antinociceptive activity of ethanol extract of leaves of Adenanthera pavonina. Evidence-Based Complementary and Alternative Medicine (IF: 2.65), Article ID 412497, 2015: 1-8. Cites: 18

  37. Moniruzzaman M*, et al. 2015. Evaluation of antinociceptive activity of ethanol extract of bark of Polyalthia longifolia. Journal of Ethnopharmacology (IF: 4.80), 172: 364-367. Cites:15

  38. Moniruzzaman M*, et al. 2015. Evaluation of sedative and hypnotic activity of ethanolic extract of Scoparia dulcis Linn. Evidence-Based Complementary and Alternative Medicine (IF: 2.65), Article ID 873954, 2015: 1-6. Cites: 57

  39. Moniruzzaman M*, et al. 2015. Evaluation of antinociceptive activity of ethanol extract of Hedyotis corymbosa Linn. whole plant in mice. Journal of Ethnopharmacology (IF: 4.80), 161: 82-85. Cites: 19

  40. Moniruzzaman M, Imam MZ*. 2014. Evaluation of antinociceptive effect of methanolic extract of leaves of Crataeva nurvala Buch.-Ham. BMC Complementary Medicine and Therapies (IF: 3.90), 14: 354. Cites: 36

  41. Imam MZ, Moniruzzaman M. 2014. Antinociceptive effect of ethanol extract of leaves of Lannea coromandelica. Journal of Ethnopharmacology (IF: 4.80), 154: 109-115. Cites: 25

bottom of page